Submit Deal

SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Summary

Swedish Orphan Biovitrum (SOBI) operates as a bio-pharmaceutical and bio-technology company. The Company develops therapies and drugs for the treatment of haemophilia, inflammation, and genetic diseases. SOBI serves clients worldwide.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 8.31 B

Avg. Deal Size£ 2.08 B

Market Context

Senior Management

Guido Oelkers
President and CEO
Henrik Karl Stenqvist
CFO
Hakan Bjorklund
Chairman

Sort

12 Jun 2019|Switzerland|Pharmaceuticals

Target: NOVIMMUNE (EMAPALUMAB AND RELATED ASSETS)

Bidder: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

9 Service Providers

6 Bidder | 3 Vendor

31 Dealmakers

13 Bidder | 18 Vendor

£ 409 M

Value

30 Sep 2019|United States|Pharmaceuticals

Target: DOVA PHARMACEUTICALS

Bidder: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

9 Service Providers

5 Target | 4 Bidder

26 Dealmakers

7 Target | 19 Bidder

£ 744 M

Value

02 Sep 2021|Sweden|Biotechnology

Target: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Bidder: ADVENT INTERNATIONAL CORPORATION

16 Service Providers

4 Target | 12 Bidder

39 Dealmakers

8 Target | 31 Bidder

£ 5.81 B

Value

10 May 2023|United States|Pharmaceuticals

Target: CTI BIOPHARMA

Bidder: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

16 Service Providers

7 Target | 9 Bidder

76 Dealmakers

26 Target | 51 Bidder

£ 1.35 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

Senior Management

Guido Oelkers
President and CEO
Henrik Karl Stenqvist
CFO
Hakan Bjorklund
Chairman